Organogenesis Holdings Inc. (ORGO)

2.0300 +0.1050 (+5.45%) At close: 04:00PM EDT

Organogenesis Holdings Inc.

85 Dan Road
Canton, MA 02021
United States
781 575 0775
https://organogenesis.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 1,030

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Gary S. Gillheeney Sr.	Pres, CEO & Director	1.61M	N/A	1955
Mr. David C. Francisco	Chief Financial Officer	553.19k	N/A	1966
Mr. Patrick Bilbo	Chief Operating Officer	741.46k	N/A	1962
Ms. Lori H. Freedman B.A., Esq., J.D.	Chief Admin. & Legal Officer	N/A	N/A	1967
Mr. Kurt Matheson	VP of Marketing	N/A	N/A	N/A
Mr. Thomas L. Pearl	VP of HR	N/A	N/A	N/A
Dr. Zorina Pitkin	Sr. VP of Quality Systems	N/A	N/A	N/A
Mr. Brian Grow	Chief Commercial Officer	N/A	N/A	1976
Mr. William R. Kolb CPA	Sec.	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly, a antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary wound covering; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly AM, PuraPly XT, and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

Corporate governance

Organogenesis Holdings Inc.’s ISS governance QualityScore as of 1 March 2023 is 8. The pillar scores are Audit: 9; Board: 9; Shareholder rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.